$Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma$

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

Purpose: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro . We sought to test the combination clinically. Experimental Design: A phase I trial evaluated sequential dose escalation of bortezomib at 1 to 1.3 mg/m 2 i.v. on days 1, 4, 8, a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2009-08, Vol.15 (16), p.5250-5257
Hauptverfasser:	Badros, Ashraf, Burger, Angelika M, Philip, Sunita, Niesvizky, Ruben, Kolla, Sarah S, Goloubeva, Olga, Harris, Carolynn, Zwiebel, James, Wright, John J, Espinoza-Delgado, Igor, Baer, Maria R, Holleran, Julianne L, Egorin, Merrill J, Grant, Steven
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Boronic Acids - administration & dosage Boronic Acids - adverse effects Bortezomib Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance, Neoplasm - drug effects Female Hematologic and hematopoietic diseases Humans Hydroxamic Acids - administration & dosage Hydroxamic Acids - adverse effects Hydroxamic Acids - pharmacokinetics Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Injections, Intravenous Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Maximum Tolerated Dose Medical sciences Middle Aged multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Multiple Myeloma - pathology Pharmacology. Drug treatments Pyrazines - administration & dosage Pyrazines - adverse effects Recurrence vorinostat
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!